Background
The Molecular Immunology Laboratory works on the immunology of malaria, cancer and autoimmunity. In 2016, the laboratory discovered Programmed cell death1 Ligand 2 (PD-L2) was contrary to dogma, not a “brake” on the immune system, but actually an essential activator of immunity. The laboratory has since then used this finding to develop multiple immunotherapies and diagnostics for the treatment of cancer and autoimmunity. The products developed from research are now developed for human treatment by the Institute’s spin-out biotech company Fovero Therapeutics. The laboratory continues to undertake basic research and have projects that would suit an Honours or PhD student.
The laboratory has discovered and developed a novel immunotherapy for colon cancer with outstanding protection. We now want to understand the mechanism of protection and if it applies to other cancers.
Aim
To dissect immune responses against cancer with the aim of developing novel immunotherapies.
Project Potential
To have an impact on cancer care.